Navigation Links
WuXi PharmaTech Provides Update of 2010 Financial Guidance, to Present at J.P. Morgan Healthcare Conference

SHANGHAI, Jan. 10, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, today announced that it will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 3:30 p.m. Pacific Standard Time and updated its 2010 financial guidance.  Based on preliminary, unaudited results, WuXi expects to slightly exceed the top end of its previous guidance for 2010 total net revenues of $330-333 million and to exceed year-over-year growth in 2010 non-GAAP operating income of 28-32%.  The company also expects to achieve the remainder of the 2010 financial guidance found in its third-quarter 2010 earnings release.

The company plans to report its audited fourth-quarter and full-year 2010 financial results and to provide 2011 financial guidance in March 2011.For more information, please contact:WuXi PharmaTech (Cayman) Inc.
Ronald Aldridge (for investors)
Director of Investor Relations
Tel: +1-201-585-2048
Email: ir@wuxiapptec.comStephanie Liu (for the media)
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.comForward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including those with respect to our financial guidance for full-year 2010 and prospects generally, anticipated customer benefits of our integrated R&D platform, expected strong performance of all our businesses and industry trends favoring outsourcing and offshoring R&D, are based on our preliminary unaudited results and subject to the completion of our 2010 audit.  Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. All projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law. Such information speaks only as of the date of this release.

Non-GAAP and Pro-Forma Financial Measures

We have provided full-year 2010 gross profit, gross margin, operating income, and operating margin on a non-GAAP basis, which excludes share-based compensation expenses, amortization of acquired intangible assets and associated deferred tax impact, expenses and termination fee relating to the proposed transaction with Charles River Laboratories, bonuses paid after the termination of the transaction, and losses from discontinued operations. We believe both management and investors benefit from referring to these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods.  These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends.  It is not practicable at this time to provide the reconciliation of our preliminary GAAP and non-GAAP results, but we will provide this information when we announce our final audited results in March 2011.   We expect to continue providing gross profit, gross margin, operating income, and operating margin on a non-GAAP basis using a consistent method on a quarterly and annual basis.  You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies.

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Presents 2010 Life Science and Chemistry Awards
2. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting
3. WuXi PharmaTech Announces Third-Quarter 2010 Results
4. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
5. WuXi PharmaTech Schedules Third-Quarter 2010 Earnings Conference Call
6. Professor Steven V. Ley Speaks at WuXi PharmaTech
7. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
8. WuXi PharmaTech Announces Second-Quarter 2010 Results
9. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):